Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CAR-T Cells(The Second Hospital of Shandong University) in Desmoplastic Small Round Cell Tumor: ISRCTN75533638 Clinical Landscape Report 2026
15 October 2026
ISRCTN75533638 clinical landscape for Desmoplastic Small Round Cell Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development whit…
9 min read
Odronextamab in Diffuse Large B-Cell Lymphoma: NCT06735664 Clinical Landscape Report 2026
15 October 2026
NCT06735664 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sintilimab in Mediastinal large B-cell lymphoma: NCT06742502 Clinical Landscape Report 2026
15 October 2026
NCT06742502 clinical landscape for Mediastinal large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Immune12 in Glioblastoma Multiforme: ACTRN12624001484538 Clinical Landscape Report 2026
15 October 2026
ACTRN12624001484538 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anzutresgene Autoleucel in Melanoma, Cutaneous Malignant: NCT06743126 Clinical Landscape Report 2026
15 October 2026
NCT06743126 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BL0175 in Ovarian Cancer: NCT06738966 Clinical Landscape Report 2026
15 October 2026
NCT06738966 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Palverafusp α in Triple Negative Breast Cancer: NCT06746870 Clinical Landscape Report 2026
15 October 2026
NCT06746870 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Endometrial Carcinoma: NCT06746116 Clinical Landscape Report 2026
15 October 2026
NCT06746116 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
DM-002 (Xadcera Biopharma) in Ovarian Cancer: NCT06751329 Clinical Landscape Report 2026
15 October 2026
NCT06751329 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Iparomlimab/Tuvonralimab in Endometrial Carcinoma: NCT06751277 Clinical Landscape Report 2026
15 October 2026
NCT06751277 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zirconium (89Zr) girentuximabum senvedoxamum in Renal Cell Carcinoma: NCT06750419 Clinical Landscape Report 2026
15 October 2026
NCT06750419 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NRG-103 in Recurrent Glioblastoma: NCT06757153 Clinical Landscape Report 2026
15 October 2026
NCT06757153 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.